Kenneth Mirkin, MD
Gastroenterology · Fairfax, VANPI 1952372542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 32.2% of the total. Reporting peaked in 2023 at $1,130 and has fallen 98.3% since, to $19 in 2025.
Across 282 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$505
- Pfizer$425
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$413
- Bristol Myers Squibb$288
- Johnson & Johnson$275
- plus $788 from 19 others
Across 102 payments — averaging $2582.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$131K
- Pfizer$88K
- Adare Pharmaceuticals, Inc.$26K
- Janssen Research & Development, LLC$11K
- AbbVie$8K
What the payments were for
- Food & beverage$3,94499%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 110 | $1,279 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $505 |
| Pfizer | 26 | $425 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $413 |
| Bristol Myers Squibb | 22 | $288 |
| Johnson & Johnson | 16 | $275 |
| Ferring Pharmaceuticals Inc. | 8 | $132 |
| Sanofi | 4 | $78 |
| Amgen | 4 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Intercept Pharmaceuticals, Inc. | 3 | $60 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Gilead | 3 | $58 |
| Braintree Laboratories, Inc. | 2 | $42 |
| Fresenius Kabi USA, LLC | 2 | $35 |
| QOL Medical, LLC | 2 | $30 |
| Celltrion USA Inc. | 1 | $29 |
| Alfasigma USA, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| UCB, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Capsovision, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$3,974 in reported general payments places this provider in the 55th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 13 | $108 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Fairfax
- Ali SiddiquiFairfax$167K
- Michael GaroneFairfax$64K
- Asma KhapraFairfax$49K
- Jeremias TanFairfax$18K
- Richard BlosserFairfax$14K
- Tonya AdamsFairfax$13K
- Larry ClarkLynchburg$1.2M
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.